RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF
Radiopharm Theranostics Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Sep 30, 2026
$0.96−0.07 (-6.50%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$6.1470 (−86.46%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Radiopharm Theranostics Ltd grew revenue 1114.3% to $3.63M over fiscal 2025.
Revenue
$3.63M
+1114.3% vs. a year earlier
Operating income
-$38.17M
FY2025
EPS, diluted
-$1.76
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.63M
- EPS, diluted
- -$1.76
Four years at a glance
Fiscal years 2022 to 2025, USD
Revenue
$3.63M+1114.3% YoY
Gross profit
$39.28K-86.9% YoY
Operating income
-$38.17M
EPS, diluted
-$1.76
Free cash flow
–
Reported period